<?xml version="1.0" encoding="UTF-8"?>
<p>CP that has been collected from individuals who have recovered from COVID-19 (ie, COVID-19 convalescent plasma [CCP]) has emerged as a leading treatment of COVID-19. Early studies in China reported benefits of CCP transfusion in patients with COVID-19, including viral clearance, radiological resolution of pulmonary disease, improved oxygenation, and survival.
 <sup>
  <xref rid="B2" ref-type="bibr">2</xref>,
  <xref rid="B3" ref-type="bibr">3</xref>
 </sup> This spurred efforts by the US Food and Drug Administration (FDA) and the US blood-banking community to collect and transfuse CCP on an unprecedented scale.
 <sup>
  <xref rid="B4" ref-type="bibr">4</xref>
 </sup> To date, over 26â€‰000 patients have been transfused with CCP in the United States alone, primarily through a government-led expanded access program.
 <sup>
  <xref rid="B5" ref-type="bibr">5</xref>
 </sup> Data gleaned from this program have shown CCP to be well tolerated, with comparable risk to standard (ie, nonimmune) plasma.
 <sup>
  <xref rid="B6" ref-type="bibr">6</xref>
 </sup>
</p>
